Certara (NASDAQ:CERT) Releases FY24 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.41-0.44 for the period, compared to the consensus estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CERT shares. Barclays cut their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday. Robert W. Baird dropped their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $15.92.

Certara Stock Performance

NASDAQ CERT traded up $0.04 during trading hours on Friday, hitting $11.03. The company had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.77 billion, a P/E ratio of -22.06, a price-to-earnings-growth ratio of 4.88 and a beta of 1.51. Certara has a fifty-two week low of $9.99 and a fifty-two week high of $19.87. The business has a fifty day simple moving average of $11.02 and a 200-day simple moving average of $13.70.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 earnings per share. Equities analysts predict that Certara will post 0.27 EPS for the current year.

Insider Activity

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.